top of page

KELLY

OFFICIAL TITLE: A PHASE II STUDY OF PEMBROLIZUMAB AND ERIBULIN IN PATIENTS WITH HRPOSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ANTHRACYCLINES AND TAXANES.

BLOG ARTICLES RELATED

home_fondo_you_barra.jpg

SCIENTIFIC IMPACT

home_fondo_you_barra.jpg

AACR 2018 – DOWNLOAD THE POSTER

SABCS 2019 – DOWNLOAD THE POSTER

CLINICAL TRIAL DETAILS

THIS A MULTICENTER, OPEN-LABEL, PHASE II CLINICAL TRIAL TO ASSESS THE EFFICACY OF PEMBROLIZUMAB IN COMBINATION WITH ERIBULIN IN FEMALE PATIENTS OLDER THAN 18 YEARS OLD WITH HORMONE RECEPTOR-(HR)POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER (MBC) PREVIOUSLY TREATED WITH AT LEAST ONE, BUT NOT MORE THAN TWO, PRIOR CHEMOTHERAPEUTIC REGIMENS FOR TREATMENT OF LOCALLY RECURRENT AND/OR METASTATIC DISEASE. PRIOR THERAPY MUST HAVE INCLUDED AN ANTHRACYCLINE AND A TAXANE. PRIOR ANTI-HORMONAL THERAPY IN THE METASTATIC DISEASE SETTING IS MANDATORY.

​

THE NUMBER OF PATIENTS TO BE INCLUDED IS 44 PATIENTS AT 11 SITES. ALL ELIGIBLE PATIENTS WILL BE TREATED WITH MK3475 (PEMBROLIZUMAB) 200 MG ON DAY 1 OF EACH 21-DAY CYCLE AND ERIBULIN 1.23 MG/M2 (EQUIVALENT TO ERIBULIN MESYLATE AT 1.4 MG/M2) ON DAYS 1 AND 8 OF EVERY 21-DAY CYCLE.

​

 

KELLY AT CLINICALTRIALS.GOV

​

RESULTS OF THE KELLY STUDY

TUMOR TYPE

PHASE

N

SITES

COUNTRY

STATUS

BREAST

II

44

11

Spain

Closing

KELLY SITES

home_fondo_you_barra.jpg

SPAIN

Hospital Clínico Universitario de Valencia

SPAIN

Instituto Oncológico Baselga - Hospital Quiron Salud Barcelona

SPAIN

Hospital Parc Taulí

SPAIN

Hospital Clínic i Provincial de Barcelona

SPAIN

MD Anderson Cancer Center Madrid

SPAIN

Hospital Universitario Ramón y Cajal

SPAIN

Complejo Hospitalario de Navarra

SPAIN

Complejo Hospitalario Universitario A Coruña (CHUAC)

SPAIN

Hospital Universitario Virgen del Rocío

SPAIN

Hospital Clínico Universitario Virgen de la Arrixaca

SPAIN

Hospital Arnau de Vilanova de Valencia

bottom of page